Bratislava Medical Journal Vol.117, No.11, p.625-627, 2016

Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.5

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.117, No.11, p.625-627, 2016
Title: Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior
Author: V. Simko

Abstract: Despite an enormous success in reducing morbidity and mortality in cardiovascular disease (CVD), statins and modern antihypertensive medications are not universally effective. Research has focused on potential molecular targets in dyslipidemia. Decades-long, expensive trial with CETP (cholesterylester transfer protein) inhibitor evacetrapib, came in April 2016 to crash landing. Despite dramatic improvement in “good” HDL-cholesterol and decline in “bad” LDL-C, the effect of evacetrapib in CVD patients was comparable to placebo. Notwithstanding failure in this molecular target field, results with another agent the PCSK9 inhibitor, may identify the molecular site that would normalize dyslipidemia, without harming physiologically essential lipids (Fig. 2, Ref. 19).

Keywords: CETP, cholesterylester transfer protein inhibitor, evacetrapib, dyslipidemia, lipoproteins, cardiovascular disease
	Published online: 22-Nov-2016
Year: 2016, Volume: 117, Issue: 11	Page From: 625, Page To: 627
doi:10.4149/BLL_2016_121
	download file

Aepress.sk